PF-303 is a covalent-reversible BTK inhibitor. Inhibitors of Bruton's tyrosine kinase (BTK) possess much promise for the treatment of oncologic and autoimmune indications. References: Benson MJ, Rodriguez V, von Schack D, Keegan S, Cook TA, Edmonds J, Benoit S, Seth N, Du S, Messing D, Nickerson-Nutter CL, Dunussi-Joannopoulos K, Rankin AL, Ruzek M, Schnute ME, Douhan J 3rd. Modeling the clinical phenotype of BTK inhibition in the mature murine immune system. J Immunol. 2014 Jul 1;193(1):185-97. doi: 10.4049/jimmunol.1302570. Epub 2014 Jun 4. PubMed PMID: 24899507.

纯度：≥98%

CAS：1609465-78-2